Steris (STE) Q2 revenue $1.6 billion vs $1.58 billion est.; adj. EPS $2.94 vs $2.70 est.; raises guidance

Steris (STE) reported fiscal 2027 second-quarter revenue of $1.6 billion, up 9% year over year and ahead of the $1.58 billion consensus, with adjusted EPS of $2.94 versus the $2.70 estimate. Net income rose to $213.7 million, or $2.19 per diluted share, from $191.9 million a year earlier, while constant currency organic revenue grew 8%. Healthcare revenue increased 9% to $1.1 billion and AST revenue rose 5% to $295.6 million, with CEO Dan Carestio citing particularly strong Life Sciences performance. The quarter included a roughly $20 million pre-tax benefit from tariff refunds, which the company said contributed to its raised outlook alongside stable underlying demand. Steris raised guidance for the year, with investors watching whether the tariff refund boost and Life Sciences momentum can be sustained into the second half.